Top

Published in:

01-10-2010 | Epidemiology

Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case–control study in Thai women

Authors: Suleeporn Sangrajrang, Yasunori Sato, Hiromi Sakamoto, Sumiko Ohnami, Thiravud Khuhaprema, Teruhiko Yoshida

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Abstract

Dietary folate as well as polymorphic variants in one-carbon metabolism genes may modulate risk of breast cancer through aberrant DNA methylation and altered nucleotide synthesis and repair. Alcohol is well recognized as a risk factor for breast cancer, and interactions with one-carbon metabolism has also been suggested. The purpose of this study is to test the hypothesis that genetic polymorphisms in the folate and alcohol metabolic pathway are associated with breast cancer risk. Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped. Five hundred and seventy patients with histopathogically confirmed breast cancer and 497 controls were included in the present study. Association of genotypes with breast cancer risk was evaluated using multivariate logistic regression to estimate odds ratios (OR) and their 95% confidence intervals (95% CI). Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18–4.16) and OR = 2.24 (95% CI 1.19–4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20–6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07–2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer. No gene–gene or gene–environment interactions were observed in this study. Our results suggest that genetic polymorphisms in folate and alcohol metabolic pathway influence the risk of breast cancer in Thai population.

Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V, Cheirsilpa A, Kanchanabat C, Khuhaprema T (2005) Cancer incidence in Thailand, 1995–1997. Asian Pac J Cancer Prev 6(3):276–281PubMed

Stover PJ (2004) Physiology of folate and vitamin B12 in health and disease. Nutr Rev 62(6Pt2):S3–S12CrossRefPubMed

Kim YI (1999) Folate and carcinogenesis: evidence, mechanisms and implications. J Nutr Biochem 10(2):66–88CrossRefPubMed

Longnecker MP (1994) Alcoholic beverage consumption in relation to risk of breast cancer: meta-analysis and review. Cancer Causes Control 5(1):73–82CrossRefPubMed

Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A, Hunter DJ (1998) Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 279(7):535–540CrossRefPubMed

Singletary KW, Gapstur SM (2001) Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 286(17):2143–2151CrossRefPubMed

Purohit V (1998) Moderate alcohol consumption and estrogen levels in postmenopausal women: a review. Alcohol Clin Exp Res 22(5):994–997CrossRefPubMed

Thomas DB (1995) Alcohol as a cause of cancer. Environ Health Perspect 103(Suppl. 8):153–160CrossRefPubMed

Feron VJ, Til HP, de Vrijer F, Woutersen RA, Cassee FR, van Bladeren PJ (1991) Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat Res 259(3–4):363–385PubMed

10.

Halsted CH, Villanueva JA, Devlin AM, Chandler CJ (2002) Metabolic interactions of alcohol and folate. J Nutr 132(Suppl. 8):2367S–2372SPubMed

11.

Zhang S, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, Holmes MD, Colditz GA, Hankinson SE (2003) Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 95(5):373–380CrossRefPubMed

12.

Rohan TE, Jain MG, Howe GR, Miller AB (2000) Dietary folate consumption and breast cancer risk. J Natl Cancer Inst 92(3):266–269CrossRefPubMed

13.

Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, Vachon CM, Olson JE, Therneau TM, Folsom AR (2001) Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 12(4):420–428CrossRefPubMed

14.

Negri E, La Vecchia C, Franceschi S (2000) Re: dietary folate consumption and breast cancer risk. J Natl Cancer Inst 92(15):1270–1271CrossRefPubMed

15.

Yoshimura K, Hanaoka T, Ohnami S, Ohnami S, Kohno T, Liu Y, Yoshida T, Sakamoto H, Tsugane S (2003) Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet 48(12):654–658CrossRefPubMed

16.

Ergul E, Sazci A, Utkan Z, Canturk NZ (2003) Polymorphisms in the MTHFR gene are associated with breast cancer. Tumor Biol 24(6):286–290CrossRef

17.

Semenza JC, Delfino RJ, Ziogas A, Anton-Culver H (2003) Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. Breast Cancer Res Treat 77(3):217–223CrossRefPubMed

18.

Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kadouri E, Friedman E (2000) Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 36(18):2313–2316CrossRefPubMed

19.

Yu CP, Wu MH, Chou YC, Yang T, You SL, Chen CJ, Sun CA (2007) Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case–control study in Taiwan. Anticancer Res 27(3B):1727–1732PubMed

20.

Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE (2004) MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 13(12):2071–2077PubMed

21.

Sharp L, Little J, Schofield AC, Pavlidou E, Cotton SC, Miedzybrodzka Z, Baird JO, Haites NE, Heys SD, Grubb DA (2002) Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 181(1):65–71CrossRefPubMed

22.

Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, Schmidt-Wolf IG, Glasmacher A, Fliessbach K, Klockgether T, Schlegel U, Pels H (2004) The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer 90(10):1969–1971CrossRefPubMed

23.

Lu CM, Chung MC, Huang CH, Ko YC (2005) Interaction effect in bladder cancer between N-acetyltransferase 2 genotype and alcohol drinking. Urol Int 75(4):360–364CrossRefPubMed

24.

Rodrigo L, Alvarez V, Rodriguez M, Pérez R, Alvarez R, Coto E (1999) N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case–control study. Scand J Gastroenterol 34(3):303–307CrossRefPubMed

25.

Hamajima N, Hirose K, Tajima K et al (2002) Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58, 515 women with breast cancer and 95, 067 women without the disease. Br J Cancer 87(11):1234–1245CrossRefPubMed

26.

Bowlin SJ, Leske MC, Varma A, Nasca P, Weinstein A, Caplan L (1997) Breast cancer risk and alcohol consumption: results from a large case–control study. Int J Epidemiol 26(5):915–923CrossRefPubMed

27.

Brodie MS, Shefner SA, Dunmiddie TV (1990) Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 508(1):65–69CrossRefPubMed

28.

Brodie MS (2002) Increased ethanol excitation of dopaminergic neurons of the ventral tegmental area after chronic ethanol treatment. Alcohol Clin Exp Res 26(7):1024–1030CrossRefPubMed

29.

McBride WJ, Chernet E, Dyr W, Lumeng L, Li TK (1993) Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol 10(5):387–390CrossRefPubMed

30.

Stefanini E, Frau M, Garau MG, Garau B, Fadda F, Gessa GL (1992) Alcohol-preferring rats have fewer dopamine D2 receptors in the limbic system. Alcohol Alcohol 27(2):127–130PubMed

31.

Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48(7):648–654PubMed

32.

Reich T, Hinrichs A, Culverhouse R, Bierut L (1999) Genetic studies of alcoholism and substance dependence. Am J Hum Genet 65(3):599–605CrossRefPubMed

33.

Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB (1990) Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 263(15):2055–2060CrossRefPubMed

34.

Bolos AM, Dean M, Lucas-Derse S, Ramsburg M, Brown GL, Goldman D (1990) Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA 264(24):3156–3160CrossRefPubMed

35.

Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, Chou YH, Yin SJ, Lu RB (2004) Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 28(3):374–384CrossRefPubMed

36.

Philibert RA, Sandhu H, Hollenbeck N, Gunter T, Adams W, Madan A (2008) The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B 147B(5):543–549CrossRef

Title: Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case–control study in Thai women
Authors: Suleeporn Sangrajrang
Yasunori Sato
Hiromi Sakamoto
Sumiko Ohnami
Thiravud Khuhaprema
Teruhiko Yoshida
Publication date: 01-10-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0804-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy

The role of RACK1 as an independent prognostic indicator in human breast cancer

Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?

Commentary on: “Effect of obesity on survival in women with breast cancer: systematic review and meta-analysis” (Melinda Protani, Michael Coory, Jennifer H. Martin)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer